Sanofi-aventis has entered an agreement to acquire TargeGen, Inc., a privately held biotechnology company focused on the development of small molecule kinase inhibitors. The final purchase price will depend on the achievement of certain future milestones, but has a potential value of $560 million. The transaction is expected to close in 3Q10. TargeGen’s most advanced drug candidate is TG101348, an oral, potent, and highly selective JAK2 kinase inhibitor being developed for the treatmen...